Acne Vulgaris Related Microbiology and Serology

Completed

Conditions studied: Acne Vulgaris

In brief

This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals. In particular, the investigators will measure serum antibody titers against P. acnes surface antigens, and the efficiency of antibody-mediated phagocytic killing of P. acnes.

Key facts

Study ID

NCT04056598

Run by

Sanofi

People needed

120

Starts

2018-01-18

Expected to finish

2019-09-30

Last updated by the study team

2021-01-06

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Acne patients (18 - 40 years of age)
• Clinical diagnosis of medium acne vulgaris (covering more than 30% of the patient's face and loaded with comedones, pustules and acne lesions of >2 cm in size) for at least six months or longer
• Clinical diagnosis of severe acne vulgaris (acne conglobata, sinus or cystic type acne covering most of the face (>60% of the facial surface) - IGA 3-4) for at least six months or longer
• Age-matched healthy adults (between 18 and 40 years), with history of moderate or severe acne, but who have been free from acne for more than two years - 'free from acne' period may include minor, intermittent breakouts due to hormonal reasons, such as menstruation

You may not qualify if…

• Subjects who received anti-acne antibiotic therapy less than 2 months prior to recruitment
• Subjects who received isotretinoin therapy within the last 6 months
• Subjects who were using hormonal contraceptives within the last 3 months

Where it is running

• Clinical Research Associates of Tidewater — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.